Etomidate for critically ill patients. Con: Do you really want to weaken the frail

European Journal of Anaesthesiology

Volumn 29, Issue 11, 2012, Pages 511-514

  De La Grandville, Beatrice ^a   Arroyo, Diego ^a   Walder, Bernhard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Adrenal insufficiency; Carboetomidate; Critical illness related corticosteroid insufficiency; Etomidate; Septic shock

Indexed keywords

ETOMIDATE; KETAMINE; MIDAZOLAM; PROPOFOL; STEROID 11BETA MONOOXYGENASE; THIOPENTAL;

ADRENAL INSUFFICIENCY; ANESTHESIA INDUCTION; CRITICAL ILLNESS; HEMODYNAMICS; HUMAN; INCIDENCE; INTENSIVE CARE; INTUBATION; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; PATIENT SAFETY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; SINGLE DRUG DOSE; SYSTEMATIC REVIEW (TOPIC);

ANESTHETICS, INTRAVENOUS; ETOMIDATE; HUMANS; HYPOTENSION;

EID: 84868600394     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1097/EJA.0b013e32835819ca     Document Type: Review

References (34)

1. Bergen JM, Smith DC. A review of etomidate for rapid sequence intubation in the emergency department. J Emerg Med 1997; 15:221-230.
2. Paris A, Philipp M, Tonner PH, et al. Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology 2003; 99:889-895.
3. Migden DR, Reardon RF. Etomidate sedation for intubation. Am J Emerg Med 1998; 16:101-102.
4. Ledingham IM, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; 1:1270.
5. de Jong FH, Mallios C, Jansen C, et al. Etomidate suppresses adrenocortical function by inhibition of 11 beta-hydroxylation. J Clin Endocrinol Metab 1984; 59:1143-1147.
6. Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987; 240:259-264.
7. Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 2001; 8:1-7.
8. Vinclair M, Broux C, Faure P, et al. Duration of adrenal inhibition following a single dose of etomidate in critically ill patients. Intensive Care Med 2008; 34:714-719.
9. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54:861-867.
10. Diago MC, Amado JA, Otero M, Lopez-Cordovilla JJ. Antiadrenal action of a subanaesthetic dose of etomidate. Anaesthesia 1988; 43:644-645.
11. Rivers EP, Katranji M, Jaehne KA, et al. Early interventions in severe sepsis and septic shock: a review of the evidence one decade later. Minerva Anestesiol 2012; 78:712-724.
12. Malerba G, Romano-Girard F, Cravoisy A, et al. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 2005; 31:388-392.
13. Iribarren JL, Jimenez JJ, Hernandez D, et al. Relative adrenal insufficiency and hemodynamic status in cardiopulmonary bypass surgery patients. A prospective cohort study. J Cardiothorac Surg 2010; 5:26.
14. Annane D. ICU physicians should abandon the use of etomidate!. Intensive Care Med 2005; 31:325-326.
15. Morris C, McAllister C. Etomidate for emergency anaesthesia: mad, bad and dangerous to know? Anaesthesia 2005; 60:737-740.
16. Murray H, Marik PE. Etomidate for endotracheal intubation in sepsis: acknowledging the good while accepting the bad. Chest 2005; 127:707-709.
17. Dmello D, Taylor S, O'Brien J, Matuschak GM. Outcomes of etomidate in severe sepsis and septic shock. Chest 2010; 138:1327-1332.
18. Ehrman R, Wira C, Lomax A, et al. Etomidate use in severe sepsis and septic shock patients does not contribute to mortality. Intern Emerg Med 2011; 6:253-257.
19. Ray DC, McKeown DW. Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock. Crit Care 2007; 11:R56.
20. Cotton BA, Guillamondegui OD, Fleming SB, et al. Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients. Arch Surg 2008; 143:62-67.
21. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871.
22. Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. Intensive Care Med 2009; 35:1868-1876.
23. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
24. Tekwani KL, Watts HF, Sweis RT, et al. A comparison of the effects of etomidate and midazolam on hospital length of stay in patients with suspected sepsis: a prospective, randomized study. Ann Emerg Med 2010; 56:481-489.
25. Albert SG, Ariyan S, Rather A. The effect of etomidate on adrenal function in critical illness: a systematic review. Intensive Care Med 2011; 37:901-910.
26. Hildreth AN, Mejia VA, Maxwell RA, et al. Adrenal suppression following a single dose of etomidate for rapid sequence induction: a prospective randomized study. J Trauma 2008; 65:573-579.
27. Roquilly A, Mahe PJ, Seguin P, et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled HYPOLYTE study. JAMA 2011; 305:1201-1209.
28. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725-2732.
29. Persson J. Wherefore ketamine? Curr Opin Anaesthesiol 2010; 23:455-460.
30. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997; 15:357-365.
31. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293-300.
32. Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. Anesthesiology 2009; 111:240-249.
33. Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. Anesthesiology 2010; 112:637-644.
34. Payen JF, Dupuis C, Trouve-Buisson T, et al. Corticosteroid after etomidate in critically ill patients: a randomized controlled trial. Crit Care Med 2012; 40:29-35.